$300.27 5.8%
BIO Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Bio-Rad

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market.

Price $300.27
Target Price Sign up
Volume 341,720
Market Cap $8.87B
Year Range $263.97 - $351.99
Dividend Yield 0%
PE Ratio 31.53
Revenue per Employee $313,655
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24600M542M326M384M546M2.290
Q4 '23681M420M366M350M338M3.100
Q3 '23621M504M336M106M156M2.330
Q2 '23669M532M363M-1.16B-1.48B3.000
Q1 '23666M582M362M69M139M3.340

Insider Transactions View All

Crowley Michael filed to sell 6,573 shares at $281.9.
June 14 '24
ERNST TIMOTHY S filed to sell 3,397 shares at $330.6.
February 29 '24
Crowley Michael filed to sell 6,942 shares at $336.
February 28 '24
WRIGHT DARA filed to sell 1,499 shares at $299.2.
December 12 '23
Crowley Michael filed to sell 6,942 shares at $305.1.
November 28 '23

Congress Trading View All

Politician Filing Date Type Size
Rohit Khanna
Nov 8, 23 Buy $1K - $15K
Rohit Khanna
Nov 8, 23 Sell $15K - $50K
Lois Frankel
Oct 10, 23 Sell $1K - $15K

What is the Market Cap of Bio-Rad?

The Market Cap of Bio-Rad is $8.87B.

What is Bio-Rad's PE Ratio?

As of today, Bio-Rad's PE (Price to Earnings) ratio is 31.53.

How Many People Work at Bio-Rad?

As of our latest update, Bio-Rad employed approximately 8,200 people worldwide. However, it's important to note that Bio-Rad's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Bio-Rad's revenue per employee?

$313,655. To calculate Bio-Rad's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Bio-Rad?

Currently, the price of one share of Bio-Rad stock is $300.27.

How can I analyze the BIO stock price chart for investment decisions?

The BIO stock price chart above provides a comprehensive visual representation of Bio-Rad's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bio-Rad shares. Our platform offers an up-to-date BIO stock price chart, along with technical data analysis and alternative data insights.

Does BIO offer dividends to its shareholders?

As of our latest update, Bio-Rad (BIO) does not offer dividends to its shareholders. Investors interested in Bio-Rad should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Bio-Rad?

Some of the similar stocks of Bio-Rad are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.